Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label study of recombinant von Willebrand factor for bleeding treatment in Chinese patients with von Willebrand disease
CTR20253153Phase 3Active
- Sponsor
- Takeda
- Start
- Nov 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of vonicog alfa in von Willebrand disease (VWD), sponsored by Takeda. Started Nov 2025; status: active.
02
Drugs
vonicog alfa
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on CTR20253153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253153.